文献速递肿瘤 PET/CT神经核医学

肠系膜纤维瘤病在18F-AlF-NOTA-奥曲肽PET/CT及增强MRI上模拟神经内分泌肿瘤转移:一例病例报告

Mesenteric Fibromatosis Mimicking Metastasis of Neuroendocrine Tumor on 18 F-AlF-NOTA-Octreotide PET/CT and Contrast- Enhanced MRI : A Case Report.
PubMed 文献 · Clin Nucl Med · 2026-06-24

一例52岁男性、既往G2胰腺神经内分泌肿瘤切除史患者,在17个月随访中新发现腹部肿块。增强MRI显示空肠肠系膜不均匀高强化病灶,高度提示转移;18F-AlF-NOTA-奥曲肽PET/CT显示病灶轻度示踪剂摄取,初始被判读为NET转移,最终手术病理证实为肠系膜纤维瘤病。本病例提示良性纤维瘤病可在解剖影像及SSTR靶向PET上模拟NET转移,需警惕误诊及不必要的治疗。

要点

  • SSTR靶向PET/CT轻度摄取并非NET转移的特异性表现,良性纤维瘤病亦可模拟。
  • 对既往NET病史患者的新发肠系膜高强化病灶,需将纤维瘤病纳入鉴别诊断。
  • 手术病理是最终确诊手段,可避免误判为转移而导致不必要的治疗。

核心结论

  • 肠系膜纤维瘤病可在增强MRI及18F-AlF-NOTA-奥曲肽PET/CT上模拟神经内分泌肿瘤转移,构成重要诊断陷阱。

研究设计与样本

  • 单例病例报告:52岁男性,既往G2胰腺神经内分泌肿瘤切除史,随访17个月时新发现腹部肿块。

主要发现

  • 增强MRI显示空肠肠系膜病灶呈不均匀高强化,高度提示转移性疾病。
  • 18F-AlF-NOTA-奥曲肽PET/CT显示病灶内轻度示踪剂摄取,初始被解读为NET转移。
  • 手术病理最终证实为肠系膜纤维瘤病。

临床怎么用

  • 对NET病史患者的新发肠系膜病灶,若SSTR靶向PET仅见轻度摄取,应警惕纤维瘤病等良性病变的可能。

局限性

  • 本文为单例病例报告,结论的普遍适用性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 52-year-old man with a prior history of resected G2 pancreatic neuroendocrine tumor presented with a newly identified abdominal mass during 17-month follow-up. Contrast-enhanced MRI depicted a heterogeneously hyper-enhancing jejunal mesenteric lesion, highly suggestive of metastatic disease. ¹⁸F-AlF-NOTA-Octreotide PET/CT revealed mild tracer accumulation within the lesion, which was initially interpreted as NET metastasis. Surgical pathology ultimately confirmed mesenteric fibromatosis. This case emphasizes an important diagnostic trap, as benign fibromatosis can mimic NET metastasis on both anatomic and SSTR-targeted PET imaging, alerting clinicians to avoid misdiagnosis and unnecessary treatment.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhuang J, Zhao G, Lu Y, et al. Mesenteric Fibromatosis Mimicking Metastasis of Neuroendocrine Tumor on 18 F-AlF-NOTA-Octreotide PET/CT and Contrast- Enhanced MRI : A Case Report. Clin Nucl Med. 2026. PMID: 42333429. doi:10.1097/RLU.0000000000006590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。